Sarepta (SPRT): FDA Request for Dystrophin Data a 'Clear Indication Willing to Grant Accelerated Approval' - Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 18.56 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.56 | 52 Week High | $63.73 | |||
| Open | $18.56 | 52 Week Low | $8.00 | |||
| Day High | $18.56 | P/E | N/A | |||
| Day Low | $18.56 | EPS | $-5.69 | |||
| Volume | 46 | |||||
